Treatments with statins for hyperlipidemia [37,38] and with pioglitazone [39], acarbose [40], and insulin [41] for diabetes have been reported to reduce the serum electronegative LDL-C levels through their effects that cause LDL-C modification, decreased systemic inflammation, and glycemic optimization. The gene discussed is INS; the disease is diabetes mellitus.